Celliaz
June 23, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Ophthalmology
Celliaz Co., Ltd. is a biotechnology company founded in 2022 at KAIST, South Korea, dedicated to developing innovative therapies to restore vision in patients with degenerative retinal diseases. Celliaz is pioneering a first-in-class retinal regeneration platform based on PROX1 modulation, which reactivates the retina’s endogenous regenerative potential.
The company is developing two core pipelines: CLZ001, an intravitreal antibody protein therapy designed for combination treatment in retinal vascular diseases such as wet age-related macular degeneration (wet-AMD), and CLZ002, an AAV-based gene therapy enabling sustained intra-retinal expression of a PROX1-neutralizing antibody, with Retinitis Pigmentosa (RP) as the primary target indication.
By focusing on functional retinal regeneration rather than disease management, Celliaz aims to establish a new therapeutic paradigm for vision restoration.
Company HQ City:
Yuseong-gu
Company HQ State:
Deajeon
Company HQ Country:
Korea, Republic of
Year Founded:
2022
CEO
Kyung Hwa Kang
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}